Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.

Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P, Gorlick R.

Pediatr Blood Cancer. 2010 Jul 15;55(1):67-75. doi: 10.1002/pbc.22479.

PMID:
20486173
2.

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu J, Smith MA.

Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6. doi: 10.1002/pbc.22367.

3.

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program.

Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA.

Mol Cancer Ther. 2010 Jan;9(1):101-12. doi: 10.1158/1535-7163.MCT-09-0952. Epub 2010 Jan 6.

4.

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ.

Cancer Res. 2009 Oct 1;69(19):7662-71. doi: 10.1158/0008-5472.CAN-09-1693. Epub 2009 Sep 29.

5.

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.

Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST, Lock R, Carol H, Reynolds CP, Maris JM, Wu J, Smith MA.

Pediatr Blood Cancer. 2009 Oct;53(4):594-8. doi: 10.1002/pbc.21989.

6.

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group.

Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22.

PMID:
18653228
7.

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA.

Pediatr Blood Cancer. 2008 Jun;50(6):1190-7. doi: 10.1002/pbc.21450.

PMID:
18260118
8.

Phase I study of everolimus in pediatric patients with refractory solid tumors.

Fouladi M, Laningham F, Wu J, O'Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL.

J Clin Oncol. 2007 Oct 20;25(30):4806-12.

9.

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA.

Pediatr Blood Cancer. 2008 Apr;50(4):799-805.

PMID:
17635004
10.

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial.

N Engl J Med. 2007 May 31;356(22):2271-81.

11.

The pediatric preclinical testing program: description of models and early testing results.

Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA.

Pediatr Blood Cancer. 2007 Dec;49(7):928-40.

PMID:
17066459
12.

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

Wan X, Harkavy B, Shen N, Grohar P, Helman LJ.

Oncogene. 2007 Mar 22;26(13):1932-40. Epub 2006 Sep 25.

PMID:
17001314
13.

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.

Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, Fouladi M, Freeman BB 3rd, Stewart CF, Houghton PJ.

Clin Cancer Res. 2006 Jan 1;12(1):223-34.

14.

Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells.

Riggi N, Cironi L, Provero P, Suvà ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A, Stamenkovic I.

Cancer Res. 2005 Dec 15;65(24):11459-68.

16.

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.

Peterson JK, Tucker C, Favours E, Cheshire PJ, Creech J, Billups CA, Smykla R, Lee FY, Houghton PJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8.

17.

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH.

J Clin Oncol. 2005 Aug 10;23(23):5347-56. Epub 2005 Jun 27.

18.
20.

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK.

Nat Med. 2002 Feb;8(2):128-35.

PMID:
11821896
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk